Skip to main content
. 2022 Sep 7;28(12):2148–2162. doi: 10.1111/cns.13956

FIGURE 6.

FIGURE 6

Case study of glioblastoma (GBM) patients who may benefit from TTF. (A) Patient A was initially diagnosed with GBM. “01.11.2021 MRI” indicated right frontal lesion with enhanced signal. Lesion was surgically removed under right frontal craniotomy: “01.19.2021 MRI”. The follow‐up MRI indicated that TT fields therapy was administered 3 months after surgery: “03.15.2021–11.24.2021 MRI”. No recurrence was detected by routine surveillance scans until 9 months after surgery. (B) Patient B was analogously detected the right frontal lesion and diagnosed with GBM. Lesion was surgically removed under right frontal craniotomy: “09.10.2021 MRI”. Unfortunately, recurrency was detected in “11.25.2021 MRI”. (C) Clinical features of patient A and B were demonstrated. Red label: initial diagnosis; Pink label: post‐surgical treatment; Blue label: no recurrency periods; Light pink label: recurrency.